XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Narrative) (Details)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
item
Sep. 30, 2019
Mar. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
Dec. 31, 2019
USD ($)
item
Jun. 30, 2020
USD ($)
Summary Of Significant Accounting Policies [Line Items]                  
Fair value of the financing derivative     $ 0         $ 0  
Financing derivative          
Continuation Advances   $ 34,000,000.0 $ 18,000,000.0   $ 52,000,000.0 $ 34,000,000      
Period in which company must repay continuation advances if change-of-control transaction is entered into with third party           2 years      
Equity or debt financing that must be raised in a single transaction           $ 100,000,000      
Period in which company must raise equity or debt financing in a single transaction           2 years      
Contingent repayment liability $ 0 0     $ 0 $ 0     $ 0
Gain from Continuation Advances   $ 34,000,000.0       34,000,000   $ 18,000,000.0  
Fair value assets/liabilities transfer between levels           $ 0      
Measurement Input, Discount Rate [Member]                  
Summary Of Significant Accounting Policies [Line Items]                  
Derivative liability, measurement input | item     0.065         0.065  
Sales Revenue, Net [Member] | Gene Company Limited [Member]                  
Summary Of Significant Accounting Policies [Line Items]                  
Concentration risk, percentage 18.00%     14.00%   14.00% 18.00%